<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03512353</url>
  </required_header>
  <id_info>
    <org_study_id>20170596</org_study_id>
    <nct_id>NCT03512353</nct_id>
  </id_info>
  <brief_title>A Study of Carfilzomib Plus Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers</brief_title>
  <official_title>An Open-label Phase 2 Study of Carfilzomib Plus Dexamethasone To Assess Tolerability and Adherence in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Describe tolerability and treatment safety of a Kd regimen (Kd 56 mg/m2 [Kd56] twice weekly
      for cycles 1-6 followed by Kd 70 mg/m2 [Kd70] once weekly for cycles 7-12) in subjects with
      relapsed or refractory multiple myeloma with 1-3 prior lines of therapy at study entry.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 18, 2018</start_date>
  <completion_date type="Anticipated">December 21, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 21, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects completing</measure>
    <time_frame>12 cycles (each cycle is 28 days)</time_frame>
    <description>Proportion of subjects completing 12 cycles of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose intensity</measure>
    <time_frame>Up to 12 cycles (each cycle is 28 days)</time_frame>
    <description>Dose intensity defined as total actual dose divided by planned dose through cycle 12 or up to disease progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose intensity</measure>
    <time_frame>6 and 12 cycles (each cycle is 28 days)</time_frame>
    <description>Dose intensity in cycles 1-6 and cycles 7-12 defined as total actual dose divided by planned dose through cycle 6 or 12 or up to disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose reductions</measure>
    <time_frame>12 cycles (each cycle is 28 days)</time_frame>
    <description>Dose reductions in cycles 1-6 and cycles 7-12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment discontinuation</measure>
    <time_frame>12 cycles (each cycle is 28 days)</time_frame>
    <description>Treatment discontinuation for all reasons in cycles 1-6 and cycles 7-12</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Relapsed or Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Carfilzomib Plus Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Describe the safety profile of carfilzomib plus dexamethasone regimen (Kd 56 mg/m2 twice weekly for cycles 1-6 followed by Kd 70 mg/m2 once weekly for cycles 7-12) in subjects with relapsed or refractory multiple myeloma (RRMM) with 1-3 prior lines of therapy at study entry. Describe subjects' adherence and satisfaction by evaluating a carfilzomib plus dexamethasone twice-weekly dosing regimen followed by a once-weekly dosing regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Describe subjects' adherence and satisfaction by evaluating a carfilzomib plus dexamethasone twice-weekly dosing regimen followed by a once-weekly dosing regimen.</description>
    <arm_group_label>Carfilzomib Plus Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Describe subjects' adherence and satisfaction by evaluating a carfilzomib plus dexamethasone twice-weekly dosing regimen followed by a once-weekly dosing regimen.</description>
    <arm_group_label>Carfilzomib Plus Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has provided informed consent prior to initiation of any study specific
             activities/procedures.

          -  Males or females greater than or equal to 18 years of age.

          -  Relapsed MM after last treatment or refractory while receiving non-proteasome
             inhibitor therapy.

          -  Measurable disease with at least 1 of the following assessed within 21 days prior to
             enrollment: immunoglobulin G (IgG) MM: serum monoclonal protein (M-protein) level
             greater than or equal to 1.0 g/dL; IgA, IgD, IgE multiple myeloma: serum M-protein
             level greater than or equal to 0.5 g/dL, urine M-protein greater than or equal to 200
             mg per 24 hours; in subjects without detectable serum or urine M-protein, serum free
             light chain (SFLC) ≥ 100 mg/L (involved light chain) and an abnormal serum kappa
             lambda ratio.

          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1.

          -  Subjects must have at least partial response (PR) to at least 1 line of prior therapy.

          -  Subjects must have received at least 1 but not more than 3 prior lines of therapy for
             MM (induction therapy followed by stem cell transplant and consolidation/maintenance
             therapy will be considered as 1 line of therapy; see Section 12.11).

          -  Prior therapy with a PI is allowed as long as the subject had at least a PR to most
             recent therapy with PI, was not removed due to toxicity (except for neuropathy, see
             criterion 213), did not relapse within 60 days from discontinuation of PI, and will
             have at least a 6-month PI treatment-free interval from last dose received until
             enrollment. (Subjects may receive maintenance therapy with drugs that are not PI
             during this 6-month PI treatment-free interval).

        Exclusion Criteria:

          -  Waldenström macroglobulinemia.

          -  Multiple myeloma of IgM subtype.

          -  POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and
             skin changes).

          -  History of plasma cell leukemia.

          -  Subjects with known amyloidosis, including amyloid deposits found on bone marrow, fat
             pad, or renal biopsy.

          -  Subjects with nephrotic range proteinuria (greater than or equal to 3 g albumin for 24
             hours urine OR greater than or equal to 2 g albumin/1 g of creatinine on a random
             urine specimen).

          -  Myelodysplastic syndrome.

          -  History of other malignancy within the past 5 years, with the following exceptions:
             Malignancy treated with curative intent and with no known active disease present for
             greater than or equal to 3 years before enrollment and felt to be at low risk for
             recurrence by the treating physician. Adequately treated non-melanoma skin cancer or
             lentigo maligna without evidence of disease. Adequately treated cervical carcinoma in
             situ without evidence of disease. Adequately treated breast ductal carcinoma in situ
             without evidence of disease. Prostatic intraepithelial neoplasia without evidence of
             prostate cancer. Adequately treated urothelial papillary noninvasive carcinoma or
             carcinoma in situ. Treated medullary or papillary thyroid cancer. Similar neoplastic
             conditions with an expectation of greater than 95% five-year disease-free survival.

          -  Known HIV infection, hepatitis C infection (subjects with hepatitis C that achieve a
             sustained virologic response following antiviral therapy are allowed), or hepatitis B
             infection (subjects with hepatitis B surface antigen or core antibody that achieve
             sustained virologic response with antiviral therapy directed at hepatitis B are
             allowed).

          -  Ongoing graft-versus-host disease.

          -  Acute active infection requiring systemic antibiotics, antifungal, antiviral (except
             antiviral therapy directed at hepatitis B) agents within 14 days prior to enrollment.

          -  Known cirrhosis.

          -  Significant neuropathy (grades 3 to 4, or grade 2 with pain) within 14 days prior to
             enrollment.

          -  Subjects with pleural effusions requiring thoracentesis or ascites requiring
             paracentesis within 14 days prior to enrollment.

          -  Uncontrolled hypertension, defined as an average systolic blood pressure greater than
             or equal to 160 mmHg or diastolic ≥ 100 mmHg despite optimal treatment.

          -  Active congestive heart failure with or without reduced ejection fraction (NYHA Class
             III to IV), symptomatic ischemia, uncontrolled arrhythmias, clinically significant
             electrocardiogram (ECG) abnormalities, screening ECG with corrected QT interval (QTc)
             of greater than 470 msec, pericardial disease, myocardial infarction within 4 months
             prior to enrollment.

          -  Known chronic obstructive pulmonary disease.

          -  Known interstitial pneumonitis.

          -  Immunotherapy within 21 days prior to enrollment.

          -  Chemotherapy with approved anticancer therapeutic within 21 days prior to enrollment.

          -  Glucocorticoid therapy (prednisone greater than 30 mg/day or equivalent) within 14
             days prior to enrollment.

          -  Focal radiation therapy within 7 days prior to enrollment. Radiation therapy to an
             extended field involving a significant volume of bone marrow within 21 days prior to
             enrollment (ie, prior radiation must have been to less than 30% of the bone marrow).

          -  Major surgery (except kyphoplasty) within 28 days prior to enrollment.

          -  Autologous or allogeneic stem cell transplant within 90 days prior to enrollment.

          -  Contraindication to dexamethasone.

          -  Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize
             carfilzomib).

          -  Intolerance to intravenous (IV) hydration.

          -  Currently receiving treatment in another investigational device or drug study, or less
             than 30 days since ending treatment on another investigational device or drug
             study(ies). Other investigational procedures while participating in this study are
             excluded.

          -  Hepatic dysfunction within 21 days prior to enrollment: bilirubin greater than or
             equal to 1.5 times the upper limit of normal (ULN); aspartate aminotransferase (AST)
             or alanine aminotransferase (ALT) greater than or equal to 3 times the ULN.

          -  Left ventricular ejection fraction less than 40% assessed by transthoracic
             echocardiogram.

          -  Severe valvular disease assessed by transthoracic echocardiogram.

          -  Severe right-ventricular dysfunction assessed by transthoracic echocardiogram.

          -  Right-ventricular systolic pressure greater than 40 mm Hg assessed by transthoracic
             echocardiogram.

          -  Intraventricular septal thickness greater than 12 mm assessed by transthoracic
             echocardiogram.

          -  Absolute neutrophil count (ANC) less than 1 x 109/L within 21 days prior to
             enrollment. Screening ANC should be independent of growth factor support for greater
             than or equal to 1 week.

          -  Hemoglobin less than 80 g/L within 21 days prior to enrollment. Use of erythropoietic
             stimulating factors and red blood cell (RBC) transfusions per institutional guidelines
             is allowed, however most recent RBC transfusion may not have been done within 7 days
             prior to obtaining screening hemoglobin.

          -  Platelet count less than 50 x 109/L (greater than or equal to 30 x 109/L if myeloma
             involvement in the bone marrow is greater than 50%) within 21 days prior to
             enrollment. Subjects should not have received platelet transfusions for at least 1
             week prior to obtaining the screening platelet count.

          -  Estimated GFR less than 30 mL/min/1.73 m2 (per the Chronic Kidney Disease Epidemiology
             Collaboration formula, see Section 12.13) within 21 days prior to enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2018</study_first_submitted>
  <study_first_submitted_qc>April 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2018</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

